Brelovitug Monotherapy Achieved 100% Virologic Response in Patients with Chronic Hepatitis D: On Treatment Week 48 Phase 2 Study Results
Agarwal, et al., Presentation, AASLD 2025
Publications &
Presentations
Our commitment to rare disease innovation is reflected in our scientific research and communications. We publish our data in peer-reviewed journals and present at leading medical and scientific conferences worldwide.
By contributing rigorous evidence to the broader scientific community, we reinforce the strength of our development and commercial programs.
Featured presentations & publications
Physician reported assessment of pruritus amongst patients with PSC: Results from a real-world survey in France, Germany, Italy and the United States
Mayo, et al., Presentation, AASLD 2025
Improvements in pruritus after maralixibat treatment are associated with improved health-related quality of life for patients with cholestatic liver disease
Miethke, et al., Presentation, NASPGHAN 2024
Evaluation of MRM-3379, a PDE4D Inhibitor, in a Mouse Model of Fragile X
Carter, et al., Presentation, FXS-NDD 2025
Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2B trial (VANTAGE): 28-week interim results
Heneghan, et al., Presentation, EASL 2025
Latest research updates
Topic
Type
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.